Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Surprising discovery about BH4 may rekindle interest in once-promising pathway

Surprising discovery about BH4 may rekindle interest in once-promising pathway

In 2013, renowned Boston Children’s Hospital pain researcher Clifford Woolf, MB, BCh, PhD, and chemist Kai Johnsson, PhD, his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. Woolf had shown that tetrahydrobioptrin — a protein also known as BH4 — is a primary natural modulator of neuropathic and inflammatory pain sensitivity. Quartet was founded on the premise that inhibiting BH4 production could prevent the progression of acute pain to chronic pain in millions of patients, without threat of addiction or tolerance.

With solid human genetic data and chemical biology, plus $17 million in series A funding, Quartet looked primed for success. But in the summer of 2017, toxicology studies of the company’s lead candidate revealed neurologic side effects. Hope for the promising pain drug cratered, taking Quartet with it.

Now, however, a surprising discovery about BH4 will likely rekindle interest in the once-promising pathway and could have profound implications for treating autoimmunity and cancer. In today’s Nature, Woolf and his team at Boston Children’s Hospital, together with immunologists from the Institute of Molecular Biotechnology (IMBA) in Vienna report that BH4 also functions as a kind of immunological thermostat in the body, raising and lowering the activity levels of T cells.

In animal models of autoimmune disease and human cell lines, the researchers were able to inhibit T cell proliferation by blockading the BH4 pathway pharmacologically. In models of cancer, they were able to enhance T cell responses by elevating BH4 levels.

“By targeting BH4, we are able to suppress T cell activity in inflammatory conditions and increase their activity in the case of cancer,” says Woolf, director of the F.M. Kirby Neurobiology Center at Boston Children’s, who co-led the study. “The ability to target the same pathway in opposite directions is significant and represents a whole new therapeutic approach.”

An immunological thermostat

Specifically, the researchers found that BH4 regulates the balance of available iron for mitochondria. To transition to an activated state, T cells need higher levels of mitochondrial energy; to produce it, mitochondria need higher levels of iron. When T cells are under pressure, the body produces more BH4, increasing the supply of available iron, allowing the cells to divide and activate. When BH4 levels are low, mitochondria can’t get the iron they need and T cell activity is suppressed. In the case of cancer, the study revealed that a metabolite produced by tumors works to block BH4, inhibiting T cell activation and cancer surveillance. It also showed that this response could be countered by augmenting BH4.

“The beauty of it is that the effect is upstream of specific types of T cell function,” says Woolf. “Most drugs being developed now to treat autoimmune conditions are targeting specific kinds of T cells. This covers them all.”

The team found that the BH4 pathway is only active in cases of infection or when proliferation needs to occur — and is not required for the normal formation of T cells.

Finally, the paper reports the development of a highly potent small molecule, QM385, that inhibits the BH4 pathway, blocking T cell proliferation and autoimmunity.

Hiding in plain sight

Shane Cronin, a post-doc researcher from Ireland, arrived in the Woolf lab in 2006. He had trained in Vienna with noted immunologist Josef Penninger, MD, PhD at IMBA, and now planned to shift his focus to the neurobiology of pain.

“I wanted to leave immunology behind,” says Cronin, lead author of the study. “Fat chance.”

Woolf’s team had just had its first major BH4 publication, which characterized the pathway as a key modulator of pain. To identify compounds that inhibit the expression of BH4, Woolf devised a drug screen using GFP fluorescent mice and asked Cronin to oversee the project.

The screen yielded plenty of hits — and for Cronin, an odd sense of déjà vu. The results pointed to the same compounds Cronin had used in his previous immunology lab to regulate T cell function.

“First I thought, okay, this is a bit of a quip, but it became very specific very quickly and I knew what I was seeing,” says Cronin. But just to be sure, he reviewed existing literature on BH4, and used reagents and technology from a neighboring immunology lab to confirm his initial finding. Woolf was intrigued and encouraged Cronin to keep exploring. But Cronin had a problem: at the time, Woolf’s lab lacked the tools and equipment for studying T cells.

When an opportunity to move back to Vienna presented itself, Cronin saw his chance. Penninger agreed to accept Cronin back into his lab at IMBA and threw his full support and knowledge behind the project. Cronin now had access to the resources and experience of one of Europe’s leading immunology labs.

“And like that, it just worked out,” says Cronin.

‘Binary’ therapeutic potential

Together, Penninger, Woolf, Cronin and the other members of the BH4 group, spent the next eight years extending their finding into models of immune-related diseases — contact dermatitis, multiple sclerosis, colitis — and finally cancer.

“There was no magic moment — just eight years of collaborative effort, putting together a puzzle, taking it apart, starting again,” says Cronin. “But I guess that’s the beauty of science–starting with a ‘that’s odd’ moment and finding something incredible.”

Working with Penninger, who co-led the study with Woolf, Cronin probed the binary therapeutic potential of BH4. If T cells proliferated in immune-related diseases, he wondered, what about cancer, where the same cells are often suppressed? Penninger and Cronin were able to boost BH4 levels in several mouse models of cancer, and the effect was immediate. Tumors shrank and the metastatic spread all but ceased.

“As a trained immunologist who was involved in defining some of the paradigmatic T cell activation pathways, I had this idea that I basically knew it all and what was left to discover would only be details,” says Penninger, who now leads the Life Sciences Institute of the University of British Columbia, Vancouver. “It was like opening an entirely new door in T cell biology – a door we can now rationally close to treat autoimmunity or keep open for T cells to kill cancer.”

Which brings us back to Quartet.

Building on a ‘successful failure’

In August of 2017, as the company neared completion of its initial IND, leadership received some troubling news. A preclinical study revealed that although the BH4-inhibiting pain drug was “on target,” it was also crossing the blood brain barrier at higher than expected levels. Because BH4 also plays an essential role in the production of key neurotransmitters, the team worried that that BH4 inhibition would reduce or prevent certain nerve signals. Ultimately, the decision was made to bring Quartet to a close.

In a blog post, Quartet chairman and founding investor Bruce Booth eulogized the company, hailing it as a “successful failure.” The company’s three-year investment had characterized the BH4 pathway in vivo in various pain models, developed and tested more than 1,500 potential BH4 inhibitors and produced a vast amount of data.

Those data can now be used to advance the new discovery toward the clinic. Woolf believes that clinical testing for immune-related diseases could begin in as early as 18 months.

“It’s unusual to start out with lots of chemistry, lots of knowledge. Normally, you’ve just got interesting biology and you have to build a startup from there,” Woolf says. “Because of the fruits of Quartet’s chemistry and data, we’re nearly ready to go.”

Keeping an open mind

Initial targets of interest for this BH4 inhibitor could include atopic dermatitis, psoriasis, systemic lupus erythematosus, polyarthritis and inflammatory bowel disease. On the oncology side, the team is starting more or less from scratch.

“We’re seeing great biological effect in terms of tumor suppression, but we still need to identify an effective pharmacological way to achieve this and address the full safety issues,” says Woolf.

The team is exploring compounds to augment BH4 in cancer patients, with the hope they could one day be used either alone or in combination with other therapies, such as immune checkpoint inhibitors. Although it’s still early, Woolf and Penninger are excited about the potential applicability of the technique, and a bit in awe of how it all came together.

“It’s just strange,” says Woolf. “I’m a neurobiologist — I never expected to be working in immunology. But these days, I guess we all try to avoid locking ourselves into silos.”

“There are many interesting discoveries to be made at the intersections and borders of fields if one keeps an open mind and is willing to follow what nature tells us,” says Penninger.

Source:

http://www.childrenshospital.org/

Tagged with:

About author

Related Articles